GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biolight Life Sciences BOLT.TA · ILA

Health Care · Tel Aviv · 🇮🇱 Israel

Compare

288.30

+0.80%

Close of 9 Nov 2026, in ILA

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in ILS, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−ILS 11.7m

FY2016FY2025

Free cash flow

−ILS 10.9m

FY2016FY2025

Shareholders' equity

ILS 34.4m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue—ILS 219,000ILS 118,000ILS 63,000ILS 3,000ILS 31,000ILS 297,000ILS 3.7mILS 1.2mILS 2.1m
Research and developmentILS 4.8mILS 3.7mILS 4.5mILS 3.5mILS 4.3mILS 4.0mILS 3.5mILS 6.2mILS 14.8mILS 11.0m
Operating income−ILS 15.2m−ILS 8.2m−ILS 26.6m−ILS 8.7m−ILS 532,000−ILS 12.8m−ILS 14.0m−ILS 18.3m−ILS 26.9m−ILS 30.4m
Net income−ILS 11.7m−ILS 7.1m−ILS 26.0m−ILS 7.8mILS 382,000−ILS 13.4m−ILS 12.6mILS 65.4m−ILS 17.3m−ILS 21.8m
Diluted earnings per share-1.40-1.53-5.59-1.720.08-2.93-2.7716.07-5.82-8.09

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsILS 42.4mILS 34.1mILS 33.5mILS 57.0mILS 64.2mILS 64.8mILS 75.0mILS 90.3mILS 24.8mILS 35.3m
Cash and short-term investmentsILS 23.7mILS 13.5mILS 8.6mILS 17.6mILS 33.7mILS 49.9mILS 40.0mILS 43.4mILS 15.8mILS 25.5m
Total liabilitiesILS 2.2mILS 3.4mILS 3.2mILS 3.3mILS 2.8mILS 4.7mILS 6.8mILS 12.5mILS 16.7mILS 18.9m
DebtILS 772,000ILS 599,000ILS 91,000ILS 527,000ILS 443,000ILS 929,000ILS 450,000———
Shareholders' equityILS 34.4mILS 26.9mILS 29.8mILS 53.2mILS 60.7mILS 59.2mILS 68.9mILS 82.3mILS 6.1mILS 10.8m
Shares outstanding8m5m5m5m5m5m5m4m3m3m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−ILS 10.9m−ILS 11.0m−ILS 9.6m−ILS 9.5m−ILS 10.0m−ILS 11.4m−ILS 15.4m−ILS 22.4m−ILS 25.3m−ILS 26.9m
Capital spending−ILS 5,000−ILS 28,000−ILS 1.4m−ILS 98,000−ILS 626,000−ILS 2.1m−ILS 29,000−ILS 54,000−ILS 117,000−ILS 370,000
Free cash flow−ILS 10.9m−ILS 11.0m−ILS 11.0m−ILS 9.6m−ILS 10.7m−ILS 13.5m−ILS 15.4m−ILS 22.4m−ILS 25.4m−ILS 27.3m

Latest quarters

By quarter end

Jun 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024
Revenue—————ILS 105,000ILS 84,000ILS 114,000
Operating income−ILS 8.0m−ILS 7.6m−ILS 3.2m−ILS 8.5m−ILS 3.9m−ILS 8.1m−ILS 2.5mILS 468,000
Net income−ILS 6.1m−ILS 5.6m−ILS 2.4m−ILS 6.1m−ILS 2.4m−ILS 8.0m−ILS 2.4mILS 838,000
Diluted earnings per share-0.67-0.67-0.45-0.73-0.52-1.71-0.520.18
Cash from operations−ILS 6.0m−ILS 5.0m−ILS 2.0m−ILS 5.0m—−ILS 6.0m—−ILS 4.0m
Total assetsILS 35.1mILS 42.4mILS 43.0mILS 26.7mILS 31.5mILS 34.1mILS 32.8mILS 35.8m
Cash and short-term investmentsILS 16.2mILS 23.7mILS 24.4mILS 7.8mILS 10.9mILS 13.5mILS 9.4mILS 13.4m
DebtILS 592,000ILS 531,000—ILS 342,000—ILS 533,000ILS 191,000ILS 533,000
Shareholders' equityILS 28.1mILS 34.4mILS 37.7mILS 20.6mILS 24.6mILS 26.9mILS 28.9mILS 31.2m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income20.5%3.6%-5.4%
Net income14.3%-2.6%-4.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-2.5-3.5-0.9-3.9138.3-2.6-3.00.8-2.5-1.6
Price to sales—115.6208.2480.1——127.514.536.116.3

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 25-to-1 reverse split · 28 Feb 2016
  • 10-to-1 reverse split · 2 Aug 2015

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.